◀ Back to IGF1
IGF1 — IGF1R
Pathways - manually collected, often from reviews:
-
OpenBEL Selventa BEL large corpus:
JAK2
→
Complex of IGF1-IGF1R
(increases)
Zong et al., J Biol Chem 2000*
Evidence: We found that STAT3, but not STAT5, was activated in response to IGF-I in 293T cells cotransfected with IGF-IR and STAT expression vectors. Moreover, tyrosine phosphorylation of STAT3, JAK1, and JAK2 was increased upon IGF-I stimulation of endogenous IGF-IR in 293T cells transfected with the respective STAT or JAK expression vector.
-
OpenBEL Selventa BEL large corpus:
Complex of IGF1-IGF1R
→
IGFBP3
(decreases)
Kuemmerle et al., Am J Physiol Gastrointest Liver Physiol 2004*
Evidence: IGFBP-3 inhibits the binding of IGF-I to its receptor and thereby inhibits IGF-I-stimulated growth.
-
OpenBEL Selventa BEL large corpus:
Complex of IGF1-IGF1R
→
IGFBP3
(decreases)
Evidence: Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) is known to block IGF action and inhibit cell growth.
-
BioCarta multiple antiapoptotic pathways from igf-1r signaling lead to bad phosphorylation:
IGF-1/IGF-1/IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta/14-3-3 complex (IGF1R-YWHAH-IGF1)
→
SHC/GRB2/SOS-1 complex (SOS1-GRB2-SHC1)
(modification, activates)
-
BioCarta igf-1 signaling pathway:
IGF-1 (IGF1)
→
IGF-1/IGF-1/IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta complex (IGF1-IGF1R)
(modification, collaborate)
-
BioCarta igf-1 signaling pathway:
IGF-1 (IGF1)
→
IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta/IRS-1 complex (IRS1-IGF1R)
(modification, collaborate)
-
BioCarta igf-1 signaling pathway:
IGF-1/IGF-1/IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta complex (IGF1-IGF1R)
→
IRS-1 (IRS1)
(modification, collaborate)
-
BioCarta igf-1 signaling pathway:
IGF-1/IGF-1/IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta complex (IGF1-IGF1R)
→
IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta/IRS-1 complex (IRS1-IGF1R)
(modification, collaborate)
-
BioCarta the igf-1 receptor and longevity:
IGF-1/IGF-1/IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta complex (IGF1-IGF1R)
→
SHC/GRB2/SOS-1 complex (SOS1-GRB2-SHC1)
(modification, activates)
-
BioCarta igf-1 signaling pathway:
IGF-1/IGF-1/IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta complex (IGF1-IGF1R)
→
SHC/GRB2/SOS-1 complex (SOS1-GRB2-SHC1)
(modification, activates)
-
BioCarta multiple antiapoptotic pathways from igf-1r signaling lead to bad phosphorylation:
IGF-1/IGF-1/IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta/14-3-3 complex (IGF1R-YWHAH-IGF1)
→
RAF1
(modification, activates)
-
BioCarta the igf-1 receptor and longevity:
IGF-1 (IGF1)
→
IGF-1/IGF-1/IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta complex (IGF1-IGF1R)
(modification, collaborate)
-
BioCarta the igf-1 receptor and longevity:
IGF-1 (IGF1)
→
IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta/IRS-1 complex (IRS1-IGF1R)
(modification, collaborate)
-
BioCarta the igf-1 receptor and longevity:
IGF-1/IGF-1/IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta complex (IGF1-IGF1R)
→
IRS-1 (IRS1)
(modification, collaborate)
-
BioCarta the igf-1 receptor and longevity:
IGF-1/IGF-1/IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta complex (IGF1-IGF1R)
→
IGF-1R-alpha/IGF-1R-alpha/IGF-1R-beta/IGF-1R-beta/IRS-1 complex (IRS1-IGF1R)
(modification, collaborate)
-
BioCarta skeletal muscle hypertrophy is regulated via akt-mtor pathway:
IGF-1/IGF-1R complex (IGF1-IGF1R)
→
PI3K complex (PIK3CA-PIK3R1)
(modification, activates)
-
BioCarta skeletal muscle hypertrophy is regulated via akt-mtor pathway:
IGF-1/IGF-1R complex (IGF1-IGF1R)
→
IGF-1 (IGF1)
(modification, collaborate)
-
BioCarta skeletal muscle hypertrophy is regulated via akt-mtor pathway:
IGF-1/IGF-1R complex (IGF1-IGF1R)
→
IGF-1R (IGF1R)
(modification, collaborate)
-
BioCarta skeletal muscle hypertrophy is regulated via akt-mtor pathway:
IGF-1 (IGF1)
→
IGF-1R (IGF1R)
(modification, collaborate)
-
KEGG Oocyte meiosis:
IGF1
→
IGF1R
(protein-protein, activation)
-
KEGG Focal adhesion:
EGF/FIGF/HGF/IGF1/PDGFA/PDGFB/PDGFC/PDGFD/PGF/VEGFA/VEGFB/VEGFC
→
EGFR/ERBB2/FLT1/FLT4/IGF1R/KDR/MET/PDGFRA/PDGFRB
(protein-protein, activation)
-
KEGG Long-term depression:
IGF1
→
IGF1R
(protein-protein, activation)
-
KEGG Progesterone-mediated oocyte maturation:
IGF1
→
IGF1R
(protein-protein, activation)
-
KEGG Pathways in cancer:
IGF1
→
IGF1R
(protein-protein, activation)
-
KEGG Glioma:
IGF1
→
IGF1R
(protein-protein, activation)
-
KEGG Glioma:
IGF1
→
IGF1R
(protein-protein, activation)
-
KEGG Prostate cancer:
EGF/IGF1/INS/PDGFA/PDGFB/PDGFC/PDGFD/TGFA
→
EGFR/ERBB2/FGFR1/FGFR2/IGF1R/INSRR/PDGFRA/PDGFRB
(protein-protein, activation)
-
KEGG Melanoma:
EGF/FGF1/FGF10/FGF11/FGF12/FGF13/FGF14/FGF16/FGF17/FGF18/FGF19/FGF2/FGF20/FGF21/FGF22/FGF23/FGF3/FGF4/FGF5/FGF6/FGF7/FGF8/FGF9/HGF/IGF1/PDGFA/PDGFB/PDGFC/PDGFD
→
EGFR/FGFR1/IGF1R/MET/PDGFRA/PDGFRB
(protein-protein, activation)
-
NCI Pathway Database Integrins in angiogenesis:
IGF-1R heterotetramer/IGF1/IRS1/Shp2 complex (IGF1R-IGF1-IRS1-PTPN11)
→
SHP2 (PTPN11)
(modification, collaborate)
Kuemmerle et al., Am J Physiol Gastrointest Liver Physiol 2006
Evidence: assay, physical interaction
-
NCI Pathway Database Integrins in angiogenesis:
IGF-1R heterotetramer/IGF1/IRS1/Shp2 complex (IGF1R-IGF1-IRS1-PTPN11)
→
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
(modification, collaborate)
Kuemmerle et al., Am J Physiol Gastrointest Liver Physiol 2006
Evidence: assay, physical interaction
-
NCI Pathway Database Integrins in angiogenesis:
SHP2 (PTPN11)
→
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
(modification, collaborate)
Kuemmerle et al., Am J Physiol Gastrointest Liver Physiol 2006
Evidence: assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1/GRB2/Sos/Shc/RACK1 complex (IGF1R-IGF1-IRS1-GNB2L1-GRB2-SHC1-SOS1)
→
PKC mu (PRKD1)
(modification, activates)
Hermanto et al., Mol Cell Biol 2002
Evidence: assay, physical interaction
-
NCI Pathway Database Plasma membrane estrogen receptor signaling:
IGF1 (IGF1)
→
IGF-1R heterotetramer complex (IGF1R)
(modification, collaborate)
Kahlert et al., J Biol Chem 2000, Song et al., Proc Natl Acad Sci U S A 2004
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database Plasma membrane estrogen receptor signaling:
IGF1 (IGF1)
→
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
(modification, collaborate)
Kahlert et al., J Biol Chem 2000, Song et al., Proc Natl Acad Sci U S A 2004
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database Plasma membrane estrogen receptor signaling:
E2/ER alpha (dimer)/PELP1/Src/p52 SHC complex (ESR1-PELP1-SRC-SHC1)
→
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
(modification, activates)
Kahlert et al., J Biol Chem 2000, Song et al., Proc Natl Acad Sci U S A 2004
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database Plasma membrane estrogen receptor signaling:
IGF-1R heterotetramer complex (IGF1R)
→
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
(modification, collaborate)
Kahlert et al., J Biol Chem 2000, Song et al., Proc Natl Acad Sci U S A 2004
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
PTP1B (PTPN1)
→
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
(modification, collaborate)
Buckley et al., Mol Pathol 2002*, Blanquart et al., Mol Pharmacol 2005*
Evidence: expresssion pattern, mutant phenotype, physical interaction
-
NCI Pathway Database IGF1 pathway:
PTP1B (PTPN1)
→
IGF-1R heterotetramer/IGF1/PTP1B complex (IGF1R-IGF1-PTPN1)
(modification, collaborate)
Buckley et al., Mol Pathol 2002*, Blanquart et al., Mol Pharmacol 2005*
Evidence: expresssion pattern, mutant phenotype, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
→
IGF-1R heterotetramer/IGF1/PTP1B complex (IGF1R-IGF1-PTPN1)
(modification, collaborate)
Buckley et al., Mol Pathol 2002*, Blanquart et al., Mol Pharmacol 2005*
Evidence: expresssion pattern, mutant phenotype, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/GRB2/Sos/Shc complex (IGF1R-IGF1-GRB2-SHC1-SOS1)
→
HRAS/GTP complex (HRAS)
(modification, activates)
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/GRB2/Sos/Shc complex (IGF1R-IGF1-GRB2-SHC1-SOS1)
→
HRAS/GDP complex (HRAS)
(modification, activates)
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1/Shp2 complex (IGF1R-IGF1-IRS1-PTPN11)
→
SHP2 (PTPN11)
(modification, collaborate)
Amoui et al., J Endocrinol 2001*
Evidence: assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1/Shp2 complex (IGF1R-IGF1-IRS1-PTPN11)
→
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
(modification, collaborate)
Amoui et al., J Endocrinol 2001*
Evidence: assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
SHP2 (PTPN11)
→
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
(modification, collaborate)
Amoui et al., J Endocrinol 2001*
Evidence: assay, physical interaction
-
NCI Pathway Database Integrins in angiogenesis:
Erk1-2 (MAPK3/MAPK1)
→
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
(modification, collaborate)
Kuemmerle et al., Am J Physiol Gastrointest Liver Physiol 2006
Evidence: assay
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
→
GRB10 (GRB10)
(modification, collaborate)
Morrione et al., Cancer Res 1996*, Dey et al., Mol Endocrinol 1996, O'Neill et al., J Biol Chem 1996, He et al., J Biol Chem 1998
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
→
IGF-1R heterotetramer/IGF1/SHC/GRB10 complex (IGF1R-IGF1-SHC1-GRB10)
(modification, collaborate)
Morrione et al., Cancer Res 1996*, Dey et al., Mol Endocrinol 1996, O'Neill et al., J Biol Chem 1996, He et al., J Biol Chem 1998
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
→
SHC (SHC1)
(modification, collaborate)
Morrione et al., Cancer Res 1996*, Dey et al., Mol Endocrinol 1996, O'Neill et al., J Biol Chem 1996, He et al., J Biol Chem 1998
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
GRB10 (GRB10)
→
IGF-1R heterotetramer/IGF1/SHC/GRB10 complex (IGF1R-IGF1-SHC1-GRB10)
(modification, collaborate)
Morrione et al., Cancer Res 1996*, Dey et al., Mol Endocrinol 1996, O'Neill et al., J Biol Chem 1996, He et al., J Biol Chem 1998
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/SHC/GRB10 complex (IGF1R-IGF1-SHC1-GRB10)
→
SHC (SHC1)
(modification, collaborate)
Morrione et al., Cancer Res 1996*, Dey et al., Mol Endocrinol 1996, O'Neill et al., J Biol Chem 1996, He et al., J Biol Chem 1998
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
→
GRB2/SOS1 complex (GRB2-SOS1)
(modification, collaborate)
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
→
IGF-1R heterotetramer/IGF1/IRS1/GRB2/Sos complex (IGF1R-IGF1-IRS1-GRB2-SOS1)
(modification, collaborate)
-
NCI Pathway Database IGF1 pathway:
GRB2/SOS1 complex (GRB2-SOS1)
→
IGF-1R heterotetramer/IGF1/IRS1/GRB2/Sos complex (IGF1R-IGF1-IRS1-GRB2-SOS1)
(modification, collaborate)
-
NCI Pathway Database Integrins in angiogenesis:
IRS1 (IRS1)
→
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
(modification, collaborate)
Kuemmerle et al., Am J Physiol Gastrointest Liver Physiol 2006
Evidence: assay, physical interaction
-
NCI Pathway Database Integrins in angiogenesis:
IGF-1R heterotetramer complex (IGF1R)
→
IGF1 (IGF1)
(modification, collaborate)
Kuemmerle et al., Am J Physiol Gastrointest Liver Physiol 2006
Evidence: assay, physical interaction
-
NCI Pathway Database Integrins in angiogenesis:
IGF-1R heterotetramer complex (IGF1R)
→
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
(modification, collaborate)
Kuemmerle et al., Am J Physiol Gastrointest Liver Physiol 2006
Evidence: assay, physical interaction
-
NCI Pathway Database Integrins in angiogenesis:
Fibronectin (FN1)
→
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
(modification, activates)
Kuemmerle et al., Am J Physiol Gastrointest Liver Physiol 2006
Evidence: assay, physical interaction
-
NCI Pathway Database Integrins in angiogenesis:
IGF1 (IGF1)
→
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
(modification, collaborate)
Kuemmerle et al., Am J Physiol Gastrointest Liver Physiol 2006
Evidence: assay, physical interaction
-
NCI Pathway Database Stabilization and expansion of the E-cadherin adherens junction:
IGF1 (IGF1)
→
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
(modification, collaborate)
Qian et al., EMBO J 2004
Evidence: assay, physical interaction
-
NCI Pathway Database Stabilization and expansion of the E-cadherin adherens junction:
IGF1 (IGF1)
→
IGF-1R heterotetramer complex (IGF1R)
(modification, collaborate)
Qian et al., EMBO J 2004
Evidence: assay, physical interaction
-
NCI Pathway Database Stabilization and expansion of the E-cadherin adherens junction:
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
→
IGF-1R heterotetramer complex (IGF1R)
(modification, collaborate)
Qian et al., EMBO J 2004
Evidence: assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IRS2/Crk complex (IRS2-CRK)
→
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
(modification, collaborate)
Beitner-Johnson et al., J Biol Chem 1996
Evidence: mutant phenotype, assay
-
NCI Pathway Database IGF1 pathway:
IGF1 (IGF1)
→
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
(modification, collaborate)
Baier et al., Eur J Cancer 1992*, LeRoith et al., Endocr Rev 1995*
-
NCI Pathway Database IGF1 pathway:
IGF1 (IGF1)
→
IGF-1R heterotetramer complex (IGF1R)
(modification, collaborate)
Baier et al., Eur J Cancer 1992*, LeRoith et al., Endocr Rev 1995*
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
→
IGF-1R heterotetramer complex (IGF1R)
(modification, collaborate)
Baier et al., Eur J Cancer 1992*, LeRoith et al., Endocr Rev 1995*
-
NCI Pathway Database Integrins in angiogenesis:
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
→
p70S6K (RPS6KB1)
(modification, activates)
Kuemmerle et al., Am J Physiol Gastrointest Liver Physiol 2006
Evidence: assay
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/GRB2/Sos/Shc complex (IGF1R-IGF1-GRB2-SHC1-SOS1)
→
IGF-1R heterotetramer/IGF1/IRS1/GRB2/Sos/Shc/RACK1 complex (IGF1R-IGF1-IRS1-GNB2L1-GRB2-SHC1-SOS1)
(modification, collaborate)
Hermanto et al., Mol Cell Biol 2002, Kiely et al., J Biol Chem 2005
Evidence: assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/GRB2/Sos/Shc complex (IGF1R-IGF1-GRB2-SHC1-SOS1)
→
RACK1 (GNB2L1)
(modification, collaborate)
Hermanto et al., Mol Cell Biol 2002, Kiely et al., J Biol Chem 2005
Evidence: assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1/GRB2/Sos/Shc/RACK1 complex (IGF1R-IGF1-IRS1-GNB2L1-GRB2-SHC1-SOS1)
→
RACK1 (GNB2L1)
(modification, collaborate)
Hermanto et al., Mol Cell Biol 2002, Kiely et al., J Biol Chem 2005
Evidence: assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
→
PI3K complex (PIK3CA-PIK3R1)
(modification, activates)
Mur et al., Endocrinology 2003
Evidence: assay
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1/GRB2/Sos/Shc/RACK1 complex (IGF1R-IGF1-IRS1-GNB2L1-GRB2-SHC1-SOS1)
→
PKC delta (PRKCD)
(modification, activates)
Hermanto et al., Mol Cell Biol 2002
Evidence: assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1/GRB2/Sos complex (IGF1R-IGF1-IRS1-GRB2-SOS1)
→
HRAS/GDP complex (HRAS)
(modification, activates)
-
NCI Pathway Database IGF1 pathway:
GRB2/SOS1/SHC complex (GRB2-SOS1-SHC1)
→
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
(modification, collaborate)
-
NCI Pathway Database IGF1 pathway:
GRB2/SOS1/SHC complex (GRB2-SOS1-SHC1)
→
IGF-1R heterotetramer/IGF1/GRB2/Sos/Shc complex (IGF1R-IGF1-GRB2-SHC1-SOS1)
(modification, collaborate)
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
→
IGF-1R heterotetramer/IGF1/GRB2/Sos/Shc complex (IGF1R-IGF1-GRB2-SHC1-SOS1)
(modification, collaborate)
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
→
Paxillin (PXN)
(modification, activates)
Butler et al., J Biol Chem 1997, Fagerström et al., J Biol Chem 1998, Casamassima et al., J Biol Chem 1998
Evidence: assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
→
CRK (CRK)
(modification, activates)
Butler et al., J Biol Chem 1997, Fagerström et al., J Biol Chem 1998, Casamassima et al., J Biol Chem 1998
Evidence: assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
→
p130 Cas (BCAR1)
(modification, activates)
Butler et al., J Biol Chem 1997, Fagerström et al., J Biol Chem 1998, Casamassima et al., J Biol Chem 1998
Evidence: assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
→
Crk/p130 Cas/Paxillin complex (CRK-BCAR1-PXN)
(modification, activates)
Butler et al., J Biol Chem 1997, Fagerström et al., J Biol Chem 1998, Casamassima et al., J Biol Chem 1998
Evidence: assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
→
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
(translocation, collaborate)
Panetta et al., Biochem Biophys Res Commun 2004*
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
→
IRS1 (IRS1)
(translocation, collaborate)
Panetta et al., Biochem Biophys Res Commun 2004*
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
→
IRS1 (IRS1)
(translocation, collaborate)
Panetta et al., Biochem Biophys Res Commun 2004*
Evidence: mutant phenotype, assay, physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
→
IRS1/NCK2 complex (NCK2-IRS1)
(modification, collaborate)
Lee et al., Proc Natl Acad Sci U S A 1993
Evidence: physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1 complex (IGF1R-IGF1)
→
IGF-1R heterotetramer/IGF1/IRS/Nck complex (IGF1R-IGF1-NCK2-IRS1)
(modification, collaborate)
Lee et al., Proc Natl Acad Sci U S A 1993
Evidence: physical interaction
-
NCI Pathway Database IGF1 pathway:
IRS1/NCK2 complex (NCK2-IRS1)
→
IGF-1R heterotetramer/IGF1/IRS/Nck complex (IGF1R-IGF1-NCK2-IRS1)
(modification, collaborate)
Lee et al., Proc Natl Acad Sci U S A 1993
Evidence: physical interaction
-
NCI Pathway Database IGF1 pathway:
IGF-1R heterotetramer/IGF1/IRS1 complex (IGF1R-IGF1-IRS1)
→
IRS1/Crk complex (IRS1-CRK)
(modification, activates)
Beitner-Johnson et al., J Biol Chem 1995*, Beitner-Johnson et al., J Biol Chem 1996, Koval et al., Biochem J 1998
Evidence: mutant phenotype, assay
-
Reactome Reaction:
IGF1R
→
IGF1
(indirect_complex)
Germain-Lee et al., Biochem J 1992*, Duronio et al., Biochem J 1990*, Keyhanfar et al., Biochem J 2007*, Bürgisser et al., J Biol Chem 1991*, Alvino et al., J Biol Chem 2009*, Alvino et al., PloS one 2011*, Cascieri et al., Biochemistry 1988*, Steele-Perkins et al., J Biol Chem 1988*, LeBon et al., J Biol Chem 1986*, Casella et al., J Biol Chem 1986*, Yu et al., J Biol Chem 1986*, Maly et al., Biochem Biophys Res Commun 1986*, Hernández-Sánchez et al., J Biol Chem 1995*
-
Reactome Reaction:
IGF1R
→
IGF1
(reaction)
Karas et al., Endocrinology 2001, Schreyer et al., Endocrinology 2003, Germain-Lee et al., Biochem J 1992*, Kim et al., Oncogene 2004, Rakatzi et al., Arch Physiol Biochem 2006, Duronio et al., Biochem J 1990*, Keyhanfar et al., Biochem J 2007*, Cuevas et al., J Hepatol 2007, Bürgisser et al., J Biol Chem 1991*, Alvino et al., J Biol Chem 2009*, Alvino et al., PloS one 2011*, Cascieri et al., Biochemistry 1988*, Steele-Perkins et al., J Biol Chem 1988*, LeBon et al., J Biol Chem 1986*, Casella et al., J Biol Chem 1986*, Yu et al., J Biol Chem 1986*, Maly et al., Biochem Biophys Res Commun 1986*, Hernández-Sánchez et al., J Biol Chem 1995*, Siemeister et al., J Biol Chem 1995, Giorgetti et al., Eur J Biochem 1994*, Xu et al., J Biol Chem 1995, Takahashi et al., Endocrinology 1997, Fantin et al., J Biol Chem 1998, Kim et al., Endocrinology 1998, Kim et al., J Biol Chem 1998
-
WikiPathways Endochondral Ossification:
IGF1
→
IGF1R
(activation)
-
WikiPathways Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling:
IGF1
→
IGF1R
(activation)
-
WikiPathways Focal Adhesion-PI3K-Akt-mTOR-signaling pathway:
EFNA1/FGF1/FGF11/FGF10/EFNA2/EGF/FGF12/CSF1/ANGPT4/ANGPT2/ANGPT1/VEGFA/EFNA3/EFNA4/EFNA5/FGF14/FGF19/FGF17/FGF18/FGF2/FGF3/FGF4/FGF6/FGF7/FGF8/FGF9/FIGF/HGF/IGF1/INS/INS/KITLG/VEGFC/VEGFB/PDGFB/PGF/PDGFA/NGF/PDGFC/FGF21/FGF22/PDGFD/FGF20/FGF16
→
FGFR2/KDR/INSR/FGFR3/IGF1R/KIT/FGFR1/EPHA2/EGFR/CSF1R/FGFR4/FLT1/FLT4/NGFR/MET/PDGFRA/PDGFRB/TEK
(activation)
-
WikiPathways Focal Adhesion:
EGF/FIGF/HGF/IGF1/PDGFA/PDGFB/PGF/PDGFC/PDGFD/VEGFA/VEGFB/VEGFC
→
BLK/EGFR/ERBB2/FGR/FLT1/HCK/IGF1R/KDR/MET/PDGFRA/PDGFRB/PTK6/SRMS/TXK/TESK2/STYK1/TNK2/TNK1
(activation)
-
WikiPathways Senescence and Autophagy in Cancer:
IGF1R
→
IGF1
(unknown)
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
-
IRef Bind Interaction:
IGF1
—
IGF1R
Fukuhara et al., Science 2005*
-
IRef Bind_translation Interaction:
IGF1
—
IGF1R
(affinity chromatography technology)
Fukuhara et al., Science 2005*
-
IRef Biogrid Interaction:
IGF1R
—
IGF1
(direct interaction, pull down)
Kjeldsen et al., Proc Natl Acad Sci U S A 1991*
-
IRef Dip Interaction:
IGF1R
—
IGF1
(direct interaction, surface plasmon resonance)
Houde et al., Structure 2011*
-
IRef Dip Interaction:
IGF1R
—
IGF1
(direct interaction, mass spectrometry study of hydrogen/deuterium exchange)
Houde et al., Structure 2011*
-
IRef Dip Interaction:
IGF1R
—
IGF1
(physical association, biochemical)
Geddes et al., Protein Eng 2001*
-
IRef Hprd Interaction:
IGF1R
—
IGF1
(in vitro)
Kjeldsen et al., Proc Natl Acad Sci U S A 1991*
-
IRef Ophid Interaction:
IGF1R
—
IGF1
(aggregation, interologs mapping)
Brown et al., Bioinformatics 2005
Text-mined interactions from Literome
Pandini et al., Clin Cancer Res 1999
(Breast Neoplasms) :
Insulin and insulin-like growth factor-I
(IGF-I) receptor overexpression in breast cancers
leads to
insulin/IGF-I hybrid receptor overexpression : evidence for a second mechanism of IGF-I signaling
Seiler et al., Alcohol Clin Exp Res 2000
(MAP Kinase Signaling System) :
Activation of the
insulin-like growth factor I receptor ( IGF-IR ) by its ligands
IGF-I and IGF-II induces cell proliferation and protects against apoptosis
Cheng et al., J Biol Chem 2000
(MAP Kinase Signaling System) :
In parallel,
IGF-I activates
IGF-I receptor , insulin receptor substrate-1 (IRS-1), phosphatidylinositol 3 (PI-3)-kinase, and FAK
Yam et al., J Biol Chem 2001
(MAP Kinase Signaling System) :
Characterization of insulin-like growth factor I
(IGF-I) receptor mutants for their
effects on
IGF-I- and interleukin 4-mediated DNA synthesis of 32D cells
Brown et al., Domest Anim Endocrinol 2001
:
Specific aims were to measure the levels of IGF binding protein-3 (IGFBP-3) and RNA encoding IGFBP-3 in the CL throughout diestrus, and to investigate the effects of IGFBP-2 and -3 on
IGF-I stimulated progesterone ( P4 ) production and
IGF-I-receptor binding
Huang et al., FEBS Lett 2001
:
SPR measurements showed that the tyrosine phosphorylation of
IGF-1R induced by its extracellular ligand
insulin-like growth factor-1 caused the receptor to bind with IRS-1 10 times faster than the unactivated receptor
Bostedt et al., Exp Cell Res 2001
(Bone Neoplasms...) :
We compared the growth rates, IGFBP production, IGF I binding characteristics,
IGF 1R protein and mRNA levels, and the acute
IGF I response ( stimulation of glycogen synthesis ) after pretreatment of the cells in serum-free medium with or without added IGF I or medium supplemented with 5 % fetal calf serum ( FCS )
Devi et al., Growth Horm IGF Res 2001
:
Effect of IGFBP-3 on IGF- and
IGF-analogue induced
insulin-like growth factor-I receptor ( IGFIR ) signalling
Oh et al., Neoplasia (New York, N.Y.) 2002
(Disease Progression...) :
Activation of the
insulin-like growth factor-1 receptor ( IGF-1R ) by
IGF-1 is associated with the risk and progression of many types of cancer, although despite this it remains unclear how activated IGF-1R contributes to cancer progression
Zizola et al., Biochimie 2002
:
We propose an autocrine and/or paracrine action of IGF-I in this adipocyte differentiation model, where
IGF-I produced by the differentiating preadipocytes acts over their adjacent cells and, in this way,
diminishes the expression of
IGF-I receptor
Mincione et al., Exp Cell Res 2003
:
Moreover, TGF-beta 1 decreased the
IGF-I induced tyrosine phosphorylation of the adaptor protein CrkII and its association with the
IGF-I receptor
Ohlsson et al., J Endocrinol 1992
:
The
effects of tri-iodothyronine ( T3 ) and
insulin-like growth factor-I (IGF-I) on [ 3H ] thymidine incorporation, alkaline phosphatase (ALP) activity and
IGF-I receptor mRNA levels were studied in rat epiphyseal chondrocytes cultured in monolayer
Sall et al., Exp Eye Res 2004
:
IGF-1 induced a dose dependent increase in
IGF-1R phosphorylation and in VEGF mRNA levels in cultured human RPE cells
Rose et al., J Biol Chem 2004
(MAP Kinase Signaling System) :
We found that
IGF-1 activated the
IGF-1R , insulin receptor substrate (IRS)-1, phosphatidylinositol 3-kinase, and Akt in a time dependent manner in alphaT3 cells
Moralez et al., J Cell Physiol 2005
(MAP Kinase Signaling System) :
When the IGFBP-5 mutant that did not bind to IGF-I was incubated with TS-1 and IGF-I, it inhibited the capacity of TS-1 to enhance the
IGF-I receptor phosphorylation and MAP kinase activation in
response to
IGF-I
Nakamura et al., Biochem Biophys Res Commun 2005
:
MMP-7 cleaved all six IGFBPs, resulting in
IGF mediated
IGF-1R phosphorylation, which was inhibited by EDTA treatment
Kuemmerle et al., Am J Physiol Gastrointest Liver Physiol 2006
:
In the presence of the alpha ( v ) beta ( 3 ) -ligand fibronectin,
IGF-I stimulated
IGF-I receptor activation was augmented ... Conversely, in the presence of the alpha ( v ) beta ( 3 ) -specific disintegrin echistatin,
IGF-I stimulated
IGF-I receptor tyrosine kinase phosphorylation was inhibited ...
IGF-I stimulated
IGF-I receptor activation was accompanied by recruitment of the adapter protein IRS-1, activation of Erk1/2, p70S6 kinase, and proliferation ... The results show that occupancy of the alpha(v)beta(3)-integrin receptor modulates
IGF-I induced
IGF-I receptor activation and function in human intestinal muscle cells ... We hypothesize that the concomitant increases in the expression of alpha ( v ) beta ( 3 ) -ligands and of IGF-I in active Crohn 's disease may contribute to muscle hyperplasia and stricture formation by acting in concert to augment
IGF-I stimulated
IGF-I receptor tyrosine kinase activity and IGF-I mediated muscle cell growth
Nguyen et al., Br J Pharmacol 2005
(Body Weight) :
Intravenous
IGF-I receptor antisense
reduces IGF-IR expression and diminishes pressor responses to angiotensin II in conscious normotensive rats
Vasilcanu et al., Oncogene 2006
(Neoplasms) :
These two cell lines were demonstrated not to acquire any essential alteration in responsiveness to PPP regarding
IGF-1 induced
IGF-1R phosphorylation
Bhaumick et al., Horm Res 1991
:
Epidermal growth factor enhancement of
insulin-like growth factor-I induced down-regulation of
insulin-like growth factor I receptor in cultured placental trophoblastic cells ... The time required to initiate the
IGF-I induced down-regulation of
IGF-I receptor was reduced by 4 h in the presence of EGF
Keyhanfar et al., Hybridoma (Larchmt) 2006
:
Activation of the
IGF-1R by
IGF-I and IGF-II binding to the extracellular domains of the receptor induces mitogenic and anti-apoptotic effects, which are important events in tumor growth and survival
Aishima et al., Cancer Sci 2006
(Carcinoma, Hepatocellular...) :
IGF-I enhanced the phosphorylation of
IGF-1R , Akt and Erk1/2 in KYN-2 cells, and coadministration of IGFBP-3 blocked all types of activation by IGF-I investigated here
Duronio et al., Biochem J 1990
:
The increase in phosphorylation of insulin receptor in response to IGF-I correlated with the dose-response of
IGF-I stimulated phosphorylation of the
IGF-I receptor
Fang et al., Carcinogenesis 2007
(Prostatic Neoplasms) :
Luteolin inhibited
insulin-like growth factor 1 (IGF-1) induced activation of
IGF-1R and AKT in prostate cancer PC-3 and DU145 cells
Elliot et al., J Am Soc Nephrol 2006
(Albuminuria...) :
Mesangial cells that were isolated from S/Pla mice had an increase of
IGF-I receptor protein, and
IGF-I stimulated a TGF-beta reporter construct promoter three-fold
Zeger et al., Glia 2007
:
These results indicate that
IGF-I directly affects oligodendrocytes and myelination in vivo via IGF1R, and that
IGF1R signaling in the cells of oligodendrocyte lineage is
required for normal oligodendrocyte development and myelination
Zhang et al., Cancer Res 2007
(Breast Neoplasms) :
We used small interfering RNA ( siRNA ) technology to specifically down-regulate IGF1R by 60 % to 80 % in the MDA-435/LCC6 cell line, which was sufficient to diminish
activation of
IGF1R by
IGF-I
Cahill et al., Cell Mol Neurobiol 1991
:
The tyrosine kinase activity of the
IGF-I receptor presumably
mediates the effects of
IGF-I on chromaffin cell function
Niu et al., J Biol Chem 2007
(Atherosclerosis...) :
IGF-1 markedly
enhanced IGF-1R phosphorylation in both wild-type and LAR ( -/- ) VSMC, but the phosphorylation was 90 % higher in knock-out cells compared with wild-type cells
Chabrolle et al., Reproduction 2007
:
Furthermore, it improved
IGF-I induced
IGF-I receptor-beta subunit tyrosine phosphorylation and ERK1/2 phosphorylation
Gauguin et al., J Biol Chem 2008
:
Evidence suggests that
insulin-like growth factor-I (IGF-I) may
activate the
IGF-I receptor in a similar mode
Xi et al., Mol Endocrinol 2008
:
In contrast, knockdown of p66shc did not affect
IGF-I stimulated
IGF-I receptor tyrosine phosphorylation
Sunstrom et al., Cytotechnology 1998
:
In particular, the expression of the endogenous
IGF-I receptor in
response to
IGF-I production has not been reported
Broussas et al., Int J Cancer 2009
(MAP Kinase Signaling System) :
Here, we showed that h7C10 inhibited
IGF-1 induced
IGF-1R phosphorylation in a dose dependent manner
Chen et al., J Nutr 2009
(Prostatic Neoplasms) :
At nutritionally relevant concentrations ( 20-60 micromol/L ), enterolactone inhibited
IGF-1 induced
activation of
IGF-1R and its downstream AKT and mitogen activated protein kinase/extracellular-signal regulated kinase signaling pathways
Barbosa et al., Pituitary 2011
(Acromegaly...) :
It is known that GH and
IGF-I can
activate B cell lymphocytes, and that
IGF-I receptor is universally expressed in MM cells
Saegusa et al., J Biol Chem 2009
:
Furthermore wild type IGF-1 mediated co-precipitation of alphavbeta3 and IGF1R, whereas the R36E/R37E mutant did not, suggesting that
IGF-1 mediates the interaction between alphavbeta3 and
IGF1R
Giovannone et al., Hum Mol Genet 2009
(Disease Models, Animal...) :
Primary cultured embryo fibroblasts from Gigyf2 null mice exhibit decreased
IGF-I stimulated
IGF-I receptor tyrosine phosphorylation and augmented ERK1/2 phosphorylation
Mani et al., Reproduction 2010
:
IGF1 with FSH
resulted in a synergistic increase in granulosa cell number and in mRNA expression of CYP19A1 and
IGF1R without altering OE(2) production
Park et al., Haematologica 2010
(Leukemia, Myeloid, Acute) :
Constitutive
PI3K activation is the
result of autocrine
IGF-1/IGF-1R signaling in 70 % of acute myeloid leukemia samples but specific inhibition of this pathway does not induce apoptosis
Chapuis et al., Haematologica 2010
(Blast Crisis...) :
Autocrine
IGF-1/IGF-1R signaling is
responsible for constitutive
PI3K/Akt activation in acute myeloid leukemia : therapeutic value of neutralizing anti-IGF-1R antibody ... Autocrine
IGF-1/IGF-1R signaling is
responsible for constitutive
PI3K/Akt activation in acute myeloid leukemia : therapeutic value of neutralizing anti-IGF-1R antibody
Nemoto et al., Neuropharmacology 2010
:
Thus,
IGF-I down-regulated functional
IGF-I receptor via GSK-3beta inhibition and mTOR activation ; constitutive activity of GSK-3beta maintained IGF-I receptor level in nonstimulated cells ... Thus,
IGF-I down-regulated functional
IGF-I receptor via GSK-3beta inhibition and mTOR activation ; constitutive activity of GSK-3beta maintained IGF-I receptor level in nonstimulated cells
Furundzija et al., Biochem Biophys Res Commun 2010
(Atherosclerosis) :
Pharmacological blocking experiments with specific inhibitors of Akt, PKC and p38 MAP-kinase revealed that IGF-1 dependent activation of focal adhesion kinase ( FAK ) and paxillin, and consecutively IGF-1 facilitated migration, required
IGF-1/IGF-1R mediated
PI3-kinase/PKC/p38 dependent integrin inside-out signaling ... Pharmacological blocking experiments with specific inhibitors of Akt, PKC and p38 MAP-kinase revealed that
IGF-1 dependent activation of focal adhesion kinase ( FAK ) and paxillin, and consecutively IGF-1 facilitated migration,
required IGF-1/IGF-1R mediated PI3-kinase/PKC/p38 dependent integrin inside-out signaling ... Pharmacological blocking experiments with specific inhibitors of Akt, PKC and p38 MAP-kinase revealed that IGF-1 dependent activation of focal adhesion kinase ( FAK ) and paxillin, and consecutively IGF-1 facilitated migration, required
IGF-1/IGF-1R mediated
PI3-kinase/PKC/p38 dependent integrin inside-out signaling ... Pharmacological blocking experiments with specific inhibitors of Akt, PKC and p38 MAP-kinase revealed that IGF-1 dependent activation of focal adhesion kinase ( FAK ) and
paxillin , and consecutively IGF-1 facilitated migration,
required IGF-1/IGF-1R mediated PI3-kinase/PKC/p38 dependent integrin inside-out signaling
Bolós et al., J Biol Chem 2010
(Alzheimer Disease) :
The transport mechanism for
IGF-I in this specialized epithelium
involves the
IGF-I receptor and the membrane multicargo transporter megalin/LRP2
Garcia-Segura et al., Prog Brain Res 2010
:
The molecular mechanisms involved in the interaction of estradiol and IGF-I include the cross-regulation of the expression of estrogen and IGF-I receptors, the regulation of estrogen receptor mediated transcription by
IGF-I and the
regulation of
IGF-I receptor signalling by estradiol
Sugita et al., Mol Cancer Res 2010
(Neoplasm Invasiveness...) :
NO donor inhibited
insulin/IGF-I stimulated phosphorylation of insulin
receptor/IGF-I receptor , IRS-1, Akt/PKB, and glycogen synthase kinase-3beta along with decreased expression of IRS-1 protein in MIAPaCa-2 cells, whereas NO donor enhanced the phosphorylation of extracellular signal regulated kinase-1/2
Aleksic et al., Cancer Res 2010
(Breast Neoplasms...) :
The IGF dependence of these phenomena indicates a requirement for the receptor kinase, and indeed,
IGF-1R nuclear import and chromatin binding can be
blocked by a novel
IGF-1R kinase inhibitor
Cascella et al., Endocrinology 2010
:
Aldosterone resulted in significant increases in the Akt ( 1.87 ± 0.24, P < 0.001 ), MAPK ( 1.78 ± 0.13, P < 0.001 ), p70S6kinase ( 1.92 ± 0.15, P < 0.001 ),
IGF-I receptor ( 1.69 ± 0.05, P < 0.01 ), and insulin receptor substrate-1 ( 1.7 ± 0.04, P < 0.01 ) ( fold increase, mean ± SEM, n = 3 ) phosphorylation
responses to
IGF-I compared with IGF-I treatment alone
Tsai et al., J Nutr Biochem 2011
(Neovascularization, Pathologic) :
Western blotting and immunoprecipitation demonstrated that denbinobin causes more efficient inhibition of
IGF-1 induced
activation of
IGF-1R and its downstream signaling targets, including, extracellular signal regulated kinase, Akt, mTOR, p70S6K, 4EBP and cyclin D1
Huang et al., J Biol Chem 2010
:
In addition to inhibiting insulin receptor and IGF1R kinase activity by directly binding to the receptors, GRB10 can also negatively
regulate insulin and
IGF1 signaling by mediating insulin receptor and
IGF1R degradation through ubiquitination
Riesterer et al., Int J Radiat Oncol Biol Phys 2011
(Carcinoma, Non-Small-Cell Lung...) :
Cell lines were assessed for
IGF-1R expression and
IGF1 dependent
response to A12 or radiation using viability and clonogenic cancer cell survival assays
Sanchez-Alavez et al., J Biol Chem 2011
(Fever) :
These data indicate a novel thermoregulatory
role for both
IGF-1R and neuronal insulin receptors in
IGF-1 activation of BAT and hyperthermia
Chakravarti et al., Mol Cell Endocrinol 2011
(Breast Neoplasms) :
Accordingly THBP was found to inhibit
IGF-1 induced phosphorylation of
IGF-1R and insulin receptor substrate-1 (IRS-1) without inhibiting insulin signaling in MCF-7 cells
Jaquish et al., Carcinogenesis 2011
(Pancreatic Neoplasms) :
IGF-1 induces rapid phosphorylation of RON, but RON signaling did not
activate IGF-1R indicating unidirectional signaling between these RTKs
Zhang et al., Breast Cancer Res 2011
(Breast Neoplasms) :
In the present study, we sought to elucidate whether antiestrogen resistance is induced directly by
IGF-1R signaling in
response to its ligand
IGF-1 stimulation ... Ectopic expression of IGF-1R in ER-positive MCF7 human breast cancer cells enhanced
IGF-1R tyrosine kinase signaling in
response to
IGF-1 ligand stimulation
Steele-Perkins et al., Biochem Biophys Res Commun 1990
:
Moreover, this antibody inhibits the ability of both
IGF-I and II to
stimulate the kinase activity of the
IGF-I receptor in intact cells
King et al., Gynecol Oncol 2011
(Cystadenocarcinoma, Serous...) :
Additionally, low-grade SOC cell lines were more responsive to
IGF-1 stimulation and
IGF-1R inhibition than were high-grade lines
Jiang et al., Am J Physiol Endocrinol Metab 2011
(MAP Kinase Signaling System) :
In carp pituitary cells,
IGF-I and -II could
induce rapid phosphorylation of
IGF-I receptor , MEK1/2, ERK1/2, MKK3/6, and p38 MAPK ; and SLa and SLß secretion, protein production, and mRNA expression caused by IGF-I and -II stimulation were negated by inactivating MEK1/2 and p38 MAPK ... In carp pituitary cells,
IGF-I and -II could
induce rapid phosphorylation of
IGF-I receptor , MEK1/2, ERK1/2, MKK3/6, and p38 MAPK ; and SLa and SLß secretion, protein production, and mRNA expression caused by IGF-I and -II stimulation were negated by inactivating MEK1/2 and p38 MAPK
Huang et al., Nutr Cancer 2011
(Prostatic Neoplasms) :
These results demonstrated that Zyflamend inhibited
IGF-1 stimulated cell growth,
IGF-1R expression, and androgen receptor expression and its nuclear localization, but these effects were not dependent upon phosphatidylinositol 3-kinase/pAKT signaling
Matsumoto et al., In Vitro Cell Dev Biol Anim 2011
:
IGF1R expression is increased by SW ; however,
IGF2R expression did not
increase by SW
Bid et al., Mol Cancer Ther 2012
(Neovascularization, Pathologic...) :
Immunoprecipitation using anti-IGF-1R and anti-IN-R antibodies revealed that SCH717454 equally blocked
IGF-1 stimulated and IGF-2 stimulated
IGF-1R phosphorylation, but not IGF-2 stimulated phosphorylation of IN-R
Fujita et al., J Biol Chem 2012
:
We recently reported that
IGF1 directly binds to avß3 and
induces avß3-IGF1-IGF1R ternary complex formation ... WT
IGF1 induced
a6ß4-IGF1-IGF1R ternary complex formation, whereas R36E/R37E did not
Chand et al., J Immunol 2012
(Chronic Disease...) :
Blocking epidermal growth factor receptor or
IGF-1R activation also
suppressed IC-IGF-1 and abolished the Bcl-2 induction
Ku et al., Mol Nutr Food Res 2012
:
Furthermore, EGCG inhibited the
IGF-I stimulated phosphorylation of the
IGF-I receptor-beta ( IGF-IR ß ), the association of IGF-IR with the p66Shc protein, and the IGF-II stimulated associations of the IGF-II receptor with G ( ai-2 ) and p66Shc proteins, suggesting that EGCG selectively affects particular types of Shc and MAPK family members
Fagan et al., Cancer Res 2012
(Breast Neoplasms) :
An
IGF1R tyrosine kinase inhibitor, AEW541, with equal potency for the IGF1R and IR,
inhibited IGF-I- , IGF-II-, and insulin stimulated Akt phosphorylation, proliferation, and anchorage independent growth in parental cells
Goel et al., Cancer Discov 2012
(Prostatic Neoplasms) :
VEGF/NRP2 signaling represses
insulin-like growth factor-1 receptor ( IGF-IR ) expression and signaling, and the mechanism
involves Bmi-1 mediated transcriptional repression of the
IGF-IR
Kraus et al., Biol Chem 2012
(Prostatic Neoplasms) :
Cathepsin X deficiency leads to a reduced phosphorylation of the
IGF-I receptor in
response to
IGF-I stimulation
Fujita et al., J Biol Chem 2013
:
We reported previously that
IGF1 directly binds to avß3 and
induces avß3-IGF1-IGF1R ternary complex formation in these conditions ... Inhibitors of
IGF1R , Src, AKT, and ERK1/2 did not
suppress avß3-IGF-IGF1R ternary complex formation, suggesting that activation of these kinases are not required for ternary complex formation
Bitelman et al., Cancer Lett 2013
(Endometrial Neoplasms) :
In addition, pretreatment with MK-0646 decreased the
IGF1 induced phosphorylation of
IGF1R , AKT and ERK
Varkaris et al., Int J Cancer 2013
(Prostatic Neoplasms) :
Ligand independent
activation of
MET through
IGF-1/IGF-1R signaling
Youreva et al., Can J Physiol Pharmacol 2013
:
In this study, we determined the effect of curcumin on
IGF-1 induced phosphorylation of protein kinase B (PKB), glycogen synthase kinase-3ß ( GSK-3ß ), and
IGF-1R in VSMC
Reverchon et al., Fertil Steril 2013
(Infertility, Female) :
This was associated with a reduction in the P450 aromatase and P450scc ( cholesterol side-chain cleavage cytochromes P450 ) ( P450scc ) protein levels but not those of 3ß-hydroxysteroid dehydrogenase ( 3ß-HSD ) or steroidogenic acute regulatory protein ( StAR ) and with a decrease in
IGF-I induced
IGF-I receptor and mitogen activated protein kinase ( MAPK ) extracellular signal regulated kinase 1/2 ( ERK1/2 ) phosphorylation
Peled et al., Cellular oncology (Dordrecht) 2013
:
Neither a knock-down of
IGF-1R expression nor an
activation of the IGF1-R pathway through exogenous
IGF-1 expression affected gefitinib sensitivity
Shen et al., FEBS open bio 2012
:
We found that both
IGF-1 and sunitinib obviously down
regulated the
IGF-1R expression
Gates et al., J Recept Res 1987
:
An
IGF-I receptor monoclonal antibody ( alpha IR-3 )
inhibited 125I-IGF-I but not 125I-insulin binding
Arnqvist et al., Metabolism 1995
:
The
IGF-I receptor is highly expressed in SMCs in intact arteries and in cultured SMCs and is
activated by binding of
IGF-I to the two alpha-subunits
Lopaczynski et al., Regul Pept 1993
(Osteosarcoma) :
Insulin-like growth factor-I (IGF-I) dependent phosphorylation of the
IGF-I receptor in MG-63 cells
Reeve et al., J Biol Chem 1995
(Cell Transformation, Viral) :
The reduced growth factor requirements of murine fibroblasts transformed by simian virus 40 ( SV 40 ) have been attributed to insulin-like growth factor
(IGF)-I induction by T antigen and consequent
activation of
IGF-I receptor signaling
Rosenthal et al., J Endocrinol 1994
:
Thus,
IGF-II induces
IGF-I receptor down-regulation in muscle cells through multiple mechanisms, including decreasing IGF-I receptor mRNA and stimulating IGF-I receptor protein degradation
Doherty et al., Mol Reprod Dev 1994
:
Although mouse preimplantation embryos express transcripts for the
insulin-like growth factor-I receptor ( IGF-IR ),
IGF-I transcripts were not
detected by reverse transcription-PCR ( RT-PCR ) at any stage of preimplantation development in a previous study ( Rappolee et al., Genes Dev 6 : 939-952, 1992 )
Galiano et al., J Clin Invest 1996
(Skin Ulcer) :
Our results suggest that activation of both the
IGF-I receptor and the alpha5beta1 integrin is
required for
IGF-I to stimulate wound healing
Lee et al., J Endocrinol 1997
(Breast Neoplasms) :
Although TAM can increase IGFBP-3 expression in MCF-7 cells, and this binding protein has been shown to be able to inhibit IGF action, TAM had no effect on
IGF-I stimulated tyrosine phosphorylation of
IGF-I receptor or the downstream signaling molecule, insulin receptor substrate-1
Karas et al., J Biol Chem 1997
(Endometrial Neoplasms) :
Membrane associated insulin-like growth factor binding protein-3 inhibits
insulin-like growth factor-I induced
insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer cells
Pugliese et al., Diabetes 1997
:
Both human and rat mesangial cells grown on BSA-AGE showed increased
IGF-I and total and bioactive TGF-beta medium levels and
enhanced IGF-I, IGF-II, and TGF-beta1 gene expression, compared with cells grown on BSA, whereas total IGFBP and IGFBP-3 medium content, IGF receptor density and affinity, and
IGF-I receptor transcripts were unchanged
Sun et al., Cardiovasc Res 1998
:
NE treatment significantly increased
IGF-1 mRNA levels in both left- and right-ventricle ; however, levels of
IGF-1R increased in the left- but not the right-ventricle
Cheng et al., J Biol Chem 1998
:
We have previously shown that
insulin-like growth factor I (IGF-I) activation of the
IGF-I receptor rescues SH-SY5Y human neuroblastoma cells from high glucose mediated programmed cell death (PCD)
Schillaci et al., Cell Immunol 1998
:
Consequently the
regulation of
IGF-1R expression by
IGF-1 and the activation events in human blood T lymphocytes and the Jurkat T cell line were now investigated
Li et al., Exp Cell Res 1998
:
A well characterized substrate of the IGF-1 R, IRS-1, is constitutively phosphorylated by the Delta870-905
IGF-1 R and phosphoinositide (PI) 3-kinase activity, which is normally activated by the phosphorylation of IRS-1 following IGF-1 stimulation, is
increased even in the absence of
IGF-1
Kobari et al., Int J Pancreatol 1998
(Pancreatic Neoplasms) :
The inhibiting
IGF-1-R-Ab reduced the cell number and
suppressed the
IGF-1 stimulated increase after 24 h and later it induced an increased cell number
Lighten et al., Hum Reprod 1998
:
Immunocytochemistry using an alphaIR3 antibody confirmed the presence of
IGF-I receptor in human blastocysts and the same antibody completely
inhibited the stimulation of blastocyst formation by
IGF-I